Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RCKT
Strong SellSinkerRocket Pharmaceuticals, Inc. · Healthcare · United States · $424M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare, devastating pediatric diseases. Utilizing both ex vivo lentiviral vector (LVV) and in vivo adeno-associated virus (AAV) based gene therapy platforms, Rocket targets a range of primary immunodeficiencies and other genetic disorders. The company operates as a specialized player in the high-growth gene therapy space, aiming to deliver potentially curative treatments for severe unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 1.1M | 11.2M | — |
| EPS | -3.26 | -2.92 | -2.73 | -2.01 | — | — | -0.11 | -1.30 | — |
| Shares | 79.1M | 90.3M | 106.5M | 108.3M | +36.9% | 109.8M | — | — | — |
| Debt | 22.9M | 25.0M | 25.5M | 24.9M | 2.8% | 24.8M | — | — | — |
| Equity | 489.7M | 492.6M | 463.2M | 277.2M | -17.3% | — | — | — | — |
| Op CF | -178.1M | -194.9M | -209.7M | -190.0M | — | -170.3M | — | — | — |
| Inv CF | -69.3M | -98.1M | 131.7M | 103.8M | — | — | — | — | — |
| Fin CF | 155.3M | 208.4M | 185.7M | 0.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RCKT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RCKT | Rocket Pharmaceuticals, Inc.(you) | $424M | 10 | Strong Sell |
| GALT | Galectin Therapeutics Inc. | $405M | 11 | Strong Sell |
| ENTA | Enanta Pharmaceuticals, Inc. | $396M | 13 | Strong Sell |
| CABA | Cabaletta Bio, Inc. | $529M | 10 | Strong Sell |
| LXEO | Lexeo Therapeutics, Inc. | $399M | 7 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 8 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 16 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $339M | 9 | Strong Sell |
| UPB | Upstream Bio, Inc. | $366M | 8 | Strong Sell |
| CMPX | Compass Therapeutics, Inc. | $432M | 5 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%